Promising anticancer compounds of the type 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-ones were identified. The target compounds were readily synthesized in a large scale via a sequence of reactions starting from the commercially available primary amines. Their in vitro anti-proliferative activity has been evaluated on prostate (DU-145), colon and melanoma (A375P) human cancer cell lines. The relationships between the structure and the anticancer activity, covering all tested cancer cell lines, revealed that the compound 5c with 2,4-dimethylphenyl substituent at R 2 was the most potent with the IC 50 values in the range as low as 0.16 to 0.40 µM.
The fundamental research for the development of new drugs against cancer stands first among the priorities of life science research worldwide. 1 The systematic investigation in our research group towards the development of anticancer drugs resulted in designing new molecules based on the bicyclic tetrahydropyrazolopyridinone skeleton. The bicyclic tetrahydropyrazolopyridinones have many interesting pharmacological properties due to their analogy with purines. The core 4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c] pyridin-7-one has been reported as an inhibitor of blood coagulation factor Xa.
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Among the wide variety of synthetic compounds recognized as potential anticancer drugs, the molecules based on the 3-aminopyrazole moiety have attracted a great interest. The 3-aminopyrazole, a well known adenine mimetic pharmacophore, was found in inhibitors of several classes of kinases such as Aurora, 3 CDK-2 4a and MAP 5 kinases. These kinases have great importance as the emerging targets in oncology drug discoveries. Based on the previously reported research on the potent anticancer activity of 3-aminopyrazoles, we have incorporated tetrahydropyridinone ring in our target molecules. Herein we report the synthesis and anticancer activity of novel 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-one derivatives. SAR studies were done using biologically evaluated disubstituted tetrahydropyrazolopyridinone analogues with the aim to find better anticancer molecules.
The route adopted for the synthesis of 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-one derivatives is described in Scheme 1. The key intermediate 3-amino-6-Nsubstituted tetrahydropyrazolopyridinone 4 was synthesized in facile three steps by employing the approach reported by Blatter and Irvington.
6 with modifications to get better yield. The first step was the synthesis of N-substituted aminobutyronitrile 2 by the N-alkylation of primary amine 1 with 4-bromobutyronitrile using potassium carbonate as a base.
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Then the cyclization was accomplished by refluxing 2 with diethyl oxalate and sodium ethoxide in ethanol to give 6-Nsubstituted 2,3-dioxopiperidin-4-carbonitrile 3, 6 which upon treatment with hydrazine monohydrate in the presence of glacial acetic acid provided the required key intermediate 4 in a quantitative yield.
4b Preparation of the target compounds 5-9 were achieved by reacting the intermediate 4 with the halide A using potassium carbonate as a base; the latter was obtained by reacting 4-substituted piperazine with chloropropionyl chloride. 8 The IR, 1 H and
13
C NMR and Mass spectral data of all the newly synthesized compounds were consistent with the assigned structure. The in vitro anti-proliferative activity of all the prepared 1,6-disubstituted tetrahydropyrazolopyridinones was evaluated according to the previously reported standard procedure by our research group 10 on four different human cancer cell lines: prostate (DU-145), colon (HT-29 and HCT-116) and melanoma (A375P).
At first, we synthesized compounds 5a-j having 4-tolyl at R 1 and various substituents at R 2 position to provide some structure activity relationship data to guide the design of additional 1,6-disubstituted tetrahydropyrazolopyridinone derivatives (Table 1) . Of them, compounds 5b, 5c, 5e, 5g and 5j showed comparable activity to the reference Doxorubicin at 100 mM concentration. At lower concentrations, 10 µM and 1 µM, however, the compound 5c having 2,4-dimethylphenyl group at R 2 exhibited far superior potency compared to the rest four compounds. It inhibited the growth of the cancer cells in the range of 74-94% even at 1 µM concentration. Overall, bulky R 2 groups seemed to be good for activity, and the electronic effect of the substituents of the phenyl ring of R 2 seemed not to be a determining factor. Interestingly the pattern of methyl substitution in the dimethylphenyl substituent (R 2 ) was crucial: the activity of the compound 5b increased drastically by altering the position of a methyl on the phenyl group from 3 to 4-position to give the compound 5c. The compound 5b was almost inactive against the tested four cell lines at 10 µM and 1 µM concentrations, while the compound 5c inhibited the cell growth significantly at the same concentrations. The compound 5j also showed considerable inhibition at 10 µM concentration and was subjected to IC 50 measurement.
Based on the above results, R 1 was varied while R 2 was fixed as 2,4-dimethylphenyl group and the in vitro antiproliferative activities of the resulting compounds were evaluated ( Table 2 ). Variation of R 1 in 5c from 4-tolyl to 4-methoxyphenyl, phenyl and benzyl yielded compounds 6, 7 and 8, respectively, with significant inhibitory potential of 72-97% at 100 µM concentration on tested cancer cell lines. Except the compound 8, however, they showed far inferior anti-proliferative activity to the compound 5c at lower concentrations. The compound 8 exhibited notable inhibition of 69% and 23% on A375P cancer cell line at 10 µM and 1 µM concentrations, respectively. Significant loss in activity was observed upon changing the R 1 to furfuryl group. The compound 9 though having 2,4-dimethylphenyl at R 2 showed only modest anticancer activity of 64% and 67% at 100 µM on HCT-116 and A375P cancer cell lines, respectively.
The IC 50 values for the compounds 5c, 5j and 8, which exhibited significant inhibition at 10 µM concentrations, are summarized in Table 3 In the present study, we have discovered and explored the structure-activity relationships of 1,6-disubstituted tetrahydropyrazolopyridinones by modifying the R 1 and R 2 substituents. The R 2 group played a key role in enhancing the activity, and 2,4-dimethylphenyl and 4-tert-butylbenzyl groups were the most preferred choices in getting potent analogues. Through SAR studies, the compound 5c was identified, which has submicromolar potency on all the tested cancer cell lines and is significantly more potent than the rest of the prepared compounds. Further modification and evaluation of the compound 5c is in progress. Studies on the mode of action of these compounds are also under way. 
